June 16 (Reuters) - Medtronic PLC:
* ABRE STUDY MEETS PRIMARY SAFETY AND EFFECTIVENESS ENDPOINTS
* MEDTRONIC SELF-EXPANDING VENOUS STENT DEMONSTRATES FAVORABLE OUTCOMES IN PATIENTS WITH VENOUS OUTFLOW OBSTRUCTION
* STUDY MET ITS PRIMARY SAFETY ENDPOINT WITH A 2.0% (4/200) RATE OF MAJOR ADVERSE EVENTS WITHIN 30 DAYS
* ABRE STUDY MEETS PRIMARY SAFETY AND EFFECTIVENESS ENDPOINTS
* DATA DEMONSTRATED A FREEDOM FROM CLINICALLY DRIVEN TARGET LESION REVASCULARIZATION RATE OF 92.4%
* NO STENT FRACTURES AND NO DELAYED STENT MIGRATION OBSERVED WITHIN 12 MONTHS IN STUDY Source text for Eikon: Further company coverage:
Our Standards: The Thomson Reuters Trust Principles.